- Home
- INSW vs SDGR Comparison
INSW vs SDGR Comparison
Compare INSW & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- SDGR
- Stock Information
- Founded
- INSW 1999
- SDGR 1990
- Country
- INSW United States
- SDGR United States
- Employees
- INSW N/A
- SDGR N/A
- Industry
- INSW Semiconductors
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- INSW Technology
- SDGR Health Care
- Exchange
- INSW Nasdaq
- SDGR Nasdaq
- Market Cap
- INSW 1.7B
- SDGR 1.7B
- IPO Year
- INSW N/A
- SDGR 2020
- Fundamental
- Price
- INSW $37.06
- SDGR $21.62
- Analyst Decision
- INSW Buy
- SDGR Buy
- Analyst Count
- INSW 2
- SDGR 5
- Target Price
- INSW $52.00
- SDGR $32.80
- AVG Volume (30 Days)
- INSW 667.0K
- SDGR 1.2M
- Earning Date
- INSW 05-08-2025
- SDGR 05-07-2025
- Dividend Yield
- INSW 10.80%
- SDGR N/A
- EPS Growth
- INSW N/A
- SDGR N/A
- EPS
- INSW 6.47
- SDGR N/A
- Revenue
- INSW $860,606,000.00
- SDGR $230,492,000.00
- Revenue This Year
- INSW N/A
- SDGR $24.71
- Revenue Next Year
- INSW $2.64
- SDGR $17.64
- P/E Ratio
- INSW $5.73
- SDGR N/A
- Revenue Growth
- INSW N/A
- SDGR 22.29
- 52 Week Low
- INSW $27.20
- SDGR $16.60
- 52 Week High
- INSW $65.32
- SDGR $28.47
- Technical
- Relative Strength Index (RSI)
- INSW 53.31
- SDGR 41.07
- Support Level
- INSW $36.05
- SDGR $21.13
- Resistance Level
- INSW $38.20
- SDGR $22.00
- Average True Range (ATR)
- INSW 1.04
- SDGR 1.03
- MACD
- INSW -0.28
- SDGR -0.23
- Stochastic Oscillator
- INSW 31.09
- SDGR 30.11
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.